Literature DB >> 16777338

The use of cultured epithelial autograft in the treatment of major burn wounds: eleven years of clinical experience.

F M Wood1, M L Kolybaba, P Allen.   

Abstract

INTRODUCTION: In patients with burns involving over 50% total body surface area (TBSA), donor skin is limited. Tissue engineering, particularly cultured epithelial autograft (CEA), offers a potential solution to assist in expedient wound closure.
MATERIALS AND METHODS: Prior to 1994, the application of CEA was restricted to confluent cell sheets. The introduction of an autologous cell suspension (CellSpray) in 1994 enabled cells to be delivered to the wound via aerosol onto debrided burn and donor skin graft wound areas. This retrospective clinical audit of major burn injured patients (n=84) describes the use of CEA in those with over 50%TBSA in Western Australia (WA) between 1992 and 2002.
RESULTS: The initial introduction of CEA was as confluent sheets, as this evolved to the use of CEA in suspension there was a reduction in the required surgical intervention and total length of stay (TLOS) divided by %TBSA. DISCUSSION: With the audit covering an 11-year period, many facets of clinical burn care have evolved. The WA experience has demonstrated CEA has been positively integrated into clinical practice in association with traditional wound care techniques of skin grafting to augment wound healing.

Entities:  

Mesh:

Year:  2006        PMID: 16777338     DOI: 10.1016/j.burns.2006.02.025

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  30 in total

1.  Vascularization of the dermal support enhances wound re-epithelialization by in situ delivery of epidermal keratinocytes.

Authors:  Liana M Lugo; Pedro Lei; Stelios T Andreadis
Journal:  Tissue Eng Part A       Date:  2010-12-18       Impact factor: 3.845

2.  Design and fabrication of human skin by three-dimensional bioprinting.

Authors:  Vivian Lee; Gurtej Singh; John P Trasatti; Chris Bjornsson; Xiawei Xu; Thanh Nga Tran; Seung-Schik Yoo; Guohao Dai; Pankaj Karande
Journal:  Tissue Eng Part C Methods       Date:  2013-12-31       Impact factor: 3.056

Review 3.  A review of tissue-engineered skin bioconstructs available for skin reconstruction.

Authors:  Rostislav V Shevchenko; Stuart L James; S Elizabeth James
Journal:  J R Soc Interface       Date:  2009-10-28       Impact factor: 4.118

4. 

Authors:  G Sabeh; M Sabé; S Ishak; R Sweid
Journal:  Ann Burns Fire Disasters       Date:  2018-09-30

Review 5.  Three-Dimensional Printing and Cell Therapy for Wound Repair.

Authors:  Sylvia van Kogelenberg; Zhilian Yue; Jeremy N Dinoro; Christopher S Baker; Gordon G Wallace
Journal:  Adv Wound Care (New Rochelle)       Date:  2018-05-01       Impact factor: 4.730

6.  MMP- and TIMP-secretion by human cutaneous keratinocytes and fibroblasts--impact of coculture and hydration.

Authors:  Andrea A Tandara; Thomas A Mustoe
Journal:  J Plast Reconstr Aesthet Surg       Date:  2010-06-09       Impact factor: 2.740

7.  Expression of keratinocyte growth factor and its receptor in rat tracheal cartilage: possible involvement in wound healing of the damaged cartilage.

Authors:  Takafumi Abo; Takeshi Nagayasu; Yoshitaka Hishikawa; Tsutomu Tagawa; Atsushi Nanashima; Takatomo Yamayoshi; Keitaro Matsumoto; Shucai An; Takehiko Koji
Journal:  Acta Histochem Cytochem       Date:  2010-04-26       Impact factor: 1.938

8.  Effects of Lonomia obliqua caterpillar venom upon the proliferation and viability of cell lines.

Authors:  Tiago Elias Heinen; Caroline Brunetto de Farias; Ana Lucia Abujamra; Ronaldo Zucatelli Mendonça; Rafael Roesler; Ana Beatriz Gorini da Veiga
Journal:  Cytotechnology       Date:  2013-01-22       Impact factor: 2.058

Review 9.  Applications of stem cell biology to oculoplastic surgery.

Authors:  Michael G Daniel; Albert Y Wu
Journal:  Curr Opin Ophthalmol       Date:  2016-09       Impact factor: 3.761

Review 10.  Cell therapy in dermatology.

Authors:  Gabriela Petrof; Alya Abdul-Wahab; John A McGrath
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.